Related Experiment Video
Updated: Mar 20, 2026
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
14.7K
COPD-associated pulmonary hypertension: clinical implications and current methods for treatment
Jan Grimminger1,2,3,4,5, Hossein Ardeschir Ghofrani1,2,3,6, Nobert Weissmann1,2,3
1a University of Giessen and Marburg Lung Center (UGMLC), University of Giessen , Giessen , Germany.
Expert Review of Respiratory Medicine
|May 24, 2016
Summary
Pulmonary hypertension in chronic obstructive pulmonary disease (PH-COPD) is a severe complication with no approved treatments. Early diagnosis and expert consultation are crucial for managing this condition.
Area of Science:
- Pulmonary Medicine
- Cardiology
- Respiratory Diseases
Background:
- Chronic obstructive pulmonary disease (COPD) is a leading global cause of death.
- Pulmonary hypertension (PH) is a serious complication affecting up to 30% of COPD patients, significantly increasing mortality.
- Current treatments for PH in COPD focus on symptom management due to a lack of approved therapies and unclear treatment benefits.
Purpose of the Study:
- To review the current understanding of the pathogenesis, clinical presentation, diagnosis, and treatment of PH in COPD.
- To highlight the challenges in diagnosing and treating this condition.
- To emphasize the need for expert centers and further research.
Main Methods:
- Literature review focusing on pathogenesis, clinical aspects, diagnostics, and treatment of PH-COPD.
- Analysis of existing knowledge regarding therapeutic approaches and their efficacy.
- Synthesis of expert commentary on the current state of PH-COPD management.
Main Results:
- PH-COPD is an orphan disease with severe consequences.
- Diagnosis and appropriate treatment selection are critical but challenging.
- No officially approved treatments are currently available, despite some studies showing improvement in individuals.
Conclusions:
- Referral to an expert center is necessary for suspected PH-COPD cases.
- Diagnostics, prognostic markers, and the development of targeted therapeutic agents are key areas for future research and clinical interest.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
812
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
812
01:20COPD: Pathogenesis and Clinical Features
2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
722
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
722
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.3K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.3K